Loading...

MLTX MOONLAKE IMMUNOTHERAPEUTICS Capital Structure Changes 8-K Filing

MNLK

MLTX

MOONLAKE IMMUNOTHERAPEUTICS

(MLTX)

2025 8-K

Supply Agreement Signed

Quarterly Update

Loan Agreement Update

FDA Feedback Update

Financial Results

Trial Results Update

Financial Statements

Financial Statements

Investor Meetings

Financial Results

Financial Results

Investor Presentation

Financial Results Announcement

FDA and EMA Positive Feedba...

Annual General Meeting

Earnings Report

Financial Results Announcement

Regulatory Approval

Financial Results Announcement

Phase 2 Trial Results

Filing with Quantitative Data

Compensation Increases

Financial Results Announcement

Underwriting Agreement and ...

Annual General Meeting

Quantitative Data

Quantitative Data

Financial Results Announcement

External Links:

On November 5, 2025, MoonLake Immunotherapeutics announced a sale of 7,142,857 Class A shares at $10.50 each, aiming for $75 million in gross proceeds, with the offering expected to close on November 6, 2025.

AI Assistant

MOONLAKE IMMUNOTHERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.